AVITA Medical has delivered another encouraging clinical milestone, with six-month results strengthening the case for its Cohealyx wound treatment technology. The findings add to growing commercial momentum, including a 53% increase in quarterly revenue and improving cash flow.
For AVITA Medical Inc. (ASX: AVH), the combination of stronger clinical evidence, expanding product adoption and upgraded revenue guidance raises an important question: could the company be approaching a significant turning point towards sustainable profitability?
Key Numbers
- 11 days: Median time to skin graft readiness in the Cohealyx I study.
- 72%: Proportion of patients ready for grafting within two weeks.
- 88%: Wound healing rate at eight weeks among assessed patients.
- US$26.1 million: Q3 2026 revenue, up 53% year-on-year.
- US$92 million to US$94 million: Upgraded full-year 2026 revenue guidance.
Six-Month Results Strengthen Cohealyx's Clinical Case
AVITA Medical's latest announcement, released on 17 November 2026 in Australia, provides complete six-month follow-up results from its Cohealyx I clinical study involving 40 patients with full-thickness wounds.
The findings build on previously reported results showing a mean time to skin graft readiness of 13.6 days, compared with a 28-day historical performance benchmark derived from published studies of other dermal matrices.
Importantly, the latest follow-up provides further evidence of successful wound healing beyond the initial grafting stage.
At eight weeks after grafting, 88% of assessed patients achieved wound healing, with continued progression through 26 weeks.
Mean Vancouver Scar Scale scores improved from 5.2 at 12 weeks to 3.5 at 26 weeks, indicating improved scar characteristics.
No Cohealyx-related adverse events were reported during the follow-up period.
Microscopic examination also demonstrated tissue integration, new blood vessel formation and collagen development.
These results strengthen Cohealyx's clinical credibility, although the relatively small, single-arm study does not establish definitive superiority over competing products.
Revenue Growth Highlights Expanding Commercial Opportunity
What makes this development particularly encouraging is that AVITA Medical is already translating its broader wound care portfolio into meaningful revenue growth.
Third-quarter revenue increased 53% to US$26.1 million, supported by stronger RECELL sales and growing Cohealyx adoption.
RECELL generated US$22.4 million in US quarterly revenue, while Cohealyx contributed US$2.1 million, increasing approximately 21% from the preceding quarter.
Gross margin improved to 84%, demonstrating attractive product economics and greater manufacturing efficiency.
Financial discipline is also improving.
Quarterly net cash use declined to approximately US$600,000 from US$3.2 million in the preceding quarter, despite the company recording a US$6.2 million net loss.
At 30 September 2026, AVITA Medical held US$10.5 million in cash, cash equivalents and marketable securities.
A subsequent US$10 million credit facility drawdown strengthened liquidity, although total borrowings of US$60 million remain an important consideration.
Building a Broader Advanced Wound Care Business
AVITA Medical is expanding its commercial platform through RECELL, Cohealyx and PermeaDerm, targeting different stages of wound treatment.
Its exclusive US marketing and distribution rights for Cohealyx provide access to a complementary product alongside its established RECELL technology.
Hospital adoption is progressing, supported by additional purchasing committee approvals and expanding clinical evidence.
Another potential growth driver emerged on 4 November 2026, when US Medicare authorities finalised updated physician payment values and simplified RECELL billing codes, effective 1 January 2027.
These changes could support wider procedural adoption, although their ultimate revenue contribution remains dependent on clinical demand and hospital purchasing decisions.
Insight: Is AVITA Medical Approaching a Financial Turning Point?
We think AVITA Medical's outlook is becoming increasingly compelling as clinical validation, revenue growth and improving financial discipline reinforce one another. Its 84% gross margin suggests meaningful operating leverage could emerge as sales expand, while Cohealyx provides an additional commercial growth opportunity beyond RECELL. Importantly, declining cash use indicates progress towards a more sustainable operating model. The company remains loss-making and carries substantial debt, but its expanding product portfolio and stronger financial performance provide credible reasons for optimism. Consistent positive cash flow would represent the clearest confirmation of that progress.
What Happens Next?
AVITA Medical has upgraded its full-year 2026 revenue guidance to US$92 million to US$94 million, representing approximately 28% to 31% growth over 2025.
Management has also reaffirmed its expectation of achieving cash flow breakeven during the fourth quarter of 2026.
Delivering that milestone would strengthen confidence in the company's ability to fund future growth through operations.
Looking ahead, expanding Cohealyx adoption, continued RECELL sales growth and updated Medicare reimbursement arrangements could provide further commercial momentum into 2027.
For shareholders, the opportunity now centres on whether AVITA Medical can convert its strengthening clinical and commercial position into sustained profitability, positive cash generation and a more resilient balance sheet.